BMSEHA15
Published online 16 December 2009
Haematologica, Vol 95, Issue 2, 320-323 doi:10.3324/haematol.2009.010355
Copyright © 2010 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Steinemann et al. - Supplementary Figures
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Google Scholar
Right arrow Articles by Steinemann, D.
Right arrow Articles by Flotho, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinemann, D.
Right arrow Articles by Flotho, C.
Related Collections
Right arrowRelated Article

Myelodysplastic/Myeloproliferative Neoplasms

Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1

Doris Steinemann1, Larissa Arning2, Inka Praulich1, Manfred Stuhrmann3, Henrik Hasle4, Jan Stary5, Brigitte Schlegelberger1, Charlotte M. Niemeyer6, Christian Flotho6

1 Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany
2 Human Genetics, University of Bochum, Bochum, Germany
3 Human Genetics, Hannover Medical School, Hannover, Germany
4 Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
5 Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic
6 Pediatric Hematology and Oncology, University of Freiburg, Freiburg, Germany

Correspondence: Christian Flotho, Pädiatrische Hämatologie und Onkologie, Zentrum für Kinder- und Jugendmedizin der Universität Freiburg, Mathildenstr. 1, D-79106 Freiburg, Germany. E-mail: christian.flotho{at}uniklinik-freiburg.de

Children with neurofibromatosis type 1 (NF-1), being constitutionally deficient for one allele of the NF1 gene, are at greatly increased risk of juvenile myelomonocytic leukemia (JMML). NF1 is a negative regulator of RAS pathway activity, which has a central role in JMML. To further clarify the role of biallelic NF1 gene inactivation in the pathogenesis of JMML, we investigated the somatic NF1 lesion in 10 samples from children with JMML/NF-1. We report that two-thirds of somatic events involved loss of heterozygosity (LOH) at the NF1 locus, predominantly caused by segmental uniparental disomy of large parts of chromosome arm 17q. One-third of leukemias showed compound-heterozygous NF1-inactivating mutations. A minority of cases exhibited somatic interstitial deletions. The findings reinforce the emerging role of somatic mitotic recombination as a leukemogenic mechanism. In addition, they support the concept that biallelic NF1 inactivation in hematopoietic progenitor cells is required for transformation to JMML in children with NF-1.

Key words: mitotic recombination, NF1-inactivating mechnisms, juvenile myelomonocytic leukemia.


Related Article

Molecular basis of juvenile myelomonocytic leukemia
Andrica C.H. de Vries, C. Michael Zwaan, Marry M. van den Heuvel-Eibrink
Haematologica 2010 95: 179-182. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 haematolHome page
T. Ripperger, C. Beger, N. Rahner, K. W. Sykora, C. L. Bockmeyer, U. Lehmann, H. H. Kreipe, and B. Schlegelberger
Constitutional mismatch repair deficiency and childhood leukemia/lymphoma - report on a novel biallelic MSH6 mutation
Haematologica, May 1, 2010; 95(5): 841 - 844.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
A. C.H. de Vries, C. M. Zwaan, and M. M. van den Heuvel-Eibrink
Molecular basis of juvenile myelomonocytic leukemia
Haematologica, February 1, 2010; 95(2): 179 - 182.
[Full Text] [PDF]